WST
West Pharmaceutical Services, Inc.
Price Chart
Latest Quote
$237.50
Current Price| Previous Close | $231.12 |
| Open | $230.90 |
| Day High | $237.67 |
| Day Low | $228.83 |
| Volume | 954,211 |
Stock Information
| Quarterly Dividend / Yield | $0.88 / 0.37% |
| Shares Outstanding | 71.94M |
| Total Debt | $303.00M |
| Cash Equivalents | $628.50M |
| Revenue | $3.02B |
| Net Income | $491.70M |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $17.09B |
| P/E Ratio | 35.19 |
| EPS (TTM) | $6.75 |
| Exchange | NYQ |
đ Custom Metrics & Score
Score: 17/42| Debt to Equity | 0.11 |
| Debt to Earnings | 0.30 |
| Current Ratio | 2.79 |
| Quick Ratio | 1.88 |
| Avg Revenue Growth | 0.54% |
| Profit Margin | 17.03% |
| Return on Equity | 18.37% |
| Avg FCF Growth | -4.10% |
| FCF Yield | 1.62% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $237.50 | 1,203,500 |
| 2026-01-30 | $231.12 | 1,601,300 |
| 2026-01-29 | $232.65 | 930,200 |
| 2026-01-28 | $235.89 | 682,800 |
| 2026-01-27 | $240.31 | 935,500 |
| 2026-01-26 | $241.18 | 989,100 |
| 2026-01-23 | $236.44 | 1,929,300 |
| 2026-01-22 | $247.55 | 1,044,900 |
| 2026-01-21 | $254.93 | 1,889,400 |
| 2026-01-20 | $250.27 | 1,801,900 |
| 2026-01-16 | $259.55 | 1,505,500 |
| 2026-01-15 | $279.15 | 789,700 |
| 2026-01-14 | $274.73 | 725,700 |
| 2026-01-13 | $271.58 | 508,200 |
| 2026-01-12 | $272.66 | 776,500 |
| 2026-01-09 | $275.27 | 490,200 |
| 2026-01-08 | $274.98 | 631,100 |
| 2026-01-07 | $278.19 | 523,400 |
| 2026-01-06 | $280.57 | 1,070,100 |
| 2026-01-05 | $278.77 | 1,048,000 |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
đ° Latest News
West Pharmaceutical Services (WST) Valuation Check After Recent Share Price Pressure
Simply Wall St. âĸ 2026-01-31T22:11:22Z
Here's Why West Pharmaceutical (WST) Is a Great 'Buy the Bottom' Stock Now
Zacks âĸ 2026-01-30T14:55:02Z
3 Cash-Producing Stocks with Open Questions
StockStory âĸ 2026-01-30T04:35:43Z
COO vs. WST: Which Stock Should Value Investors Buy Now?
Zacks âĸ 2026-01-28T16:40:03Z
WST Launches Synchrony S1 Prefillable Syringe at Pharmapack
Zacks âĸ 2026-01-23T18:50:00Z
Does West Pharmaceutical (WST) Expanding Into Biologic Syringe Systems Reshape Its Combination-Product Edge?
Simply Wall St. âĸ 2026-01-23T12:13:20Z
Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical and Align Technology
Zacks âĸ 2026-01-23T08:58:00Z
All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy
Zacks âĸ 2026-01-22T17:00:04Z
BD and Ypsomed Expand Partnership to Target Growing Biologics Market
Zacks âĸ 2026-01-22T15:43:00Z
4 Medical Supply Stocks Poised to Gain in a Prospering Industry
Zacks âĸ 2026-01-22T14:09:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $1,894,700,000 | $1,820,600,000 | $1,750,700,000 | $1,655,800,000 |
| Cost Of Revenue | $1,894,700,000 | $1,820,600,000 | $1,750,700,000 | $1,655,800,000 |
| Total Revenue | $2,893,200,000 | $2,949,800,000 | $2,886,900,000 | $2,831,600,000 |
| Operating Revenue | $2,893,200,000 | $2,949,800,000 | $2,886,900,000 | $2,831,600,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $3,000,000 | $9,000,000 | $7,900,000 | $8,200,000 |
| Total Expenses | $2,302,300,000 | $2,242,400,000 | $2,126,100,000 | $2,071,400,000 |
| Other Income Expense | $-22,000,000 | $-28,400,000 | $-78,100,000 | $-4,100,000 |
| Other Non Operating Income Expenses | $-1,900,000 | $1,700,000 | $-49,200,000 | $2,100,000 |
| Net Non Operating Interest Income Expense | $16,600,000 | $19,000,000 | $-2,800,000 | $-7,200,000 |
| Interest Expense Non Operating | $3,000,000 | $9,000,000 | $7,900,000 | $8,200,000 |
| Operating Expense | $407,600,000 | $421,800,000 | $375,400,000 | $415,600,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Net Interest Income | $16,600,000 | $19,000,000 | $-2,800,000 | $-7,200,000 |
| Interest Income | $19,600,000 | $28,000,000 | $5,100,000 | $1,000,000 |
| Normalized Income | $509,101,600 | $618,232,500 | $609,915,900 | $667,113,400 |
| Net Income From Continuing And Discontinued Operation | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Total Operating Income As Reported | $569,900,000 | $676,000,000 | $734,000,000 | $752,300,000 |
| Net Income Common Stockholders | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Net Income | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Net Income Including Noncontrolling Interests | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Net Income Continuous Operations | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Earnings From Equity Interest Net Of Tax | $14,700,000 | $17,700,000 | $20,700,000 | $20,100,000 |
| Pretax Income | $585,500,000 | $698,000,000 | $679,900,000 | $748,900,000 |
| Special Income Charges | $-9,900,000 | $-20,700,000 | $-33,000,000 | $-9,300,000 |
| Interest Income Non Operating | $19,600,000 | $28,000,000 | $5,100,000 | $1,000,000 |
| Operating Income | $590,900,000 | $707,400,000 | $760,800,000 | $760,200,000 |
| Gross Profit | $998,500,000 | $1,129,200,000 | $1,136,200,000 | $1,175,800,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $6.69 | $7.88 | $7.73 | $8.67 |
| Basic EPS | $6.75 | $7.98 | $7.87 | $8.89 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-3,698,400 | $-5,267,500 | $-4,884,100 | $-886,600 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $764,000,000 | $874,400,000 | $837,300,000 | $885,600,000 |
| Total Unusual Items | $-20,100,000 | $-30,100,000 | $-28,900,000 | $-6,200,000 |
| Total Unusual Items Excluding Goodwill | $-20,100,000 | $-30,100,000 | $-28,900,000 | $-6,200,000 |
| Reconciled Depreciation | $155,400,000 | $137,300,000 | $120,600,000 | $122,300,000 |
| EBITDA (Bullshit earnings) | $743,900,000 | $844,300,000 | $808,400,000 | $879,400,000 |
| EBIT | $588,500,000 | $707,000,000 | $687,800,000 | $757,100,000 |
| Diluted Average Shares | $73,700,000 | $75,300,000 | $75,800,000 | $76,300,000 |
| Basic Average Shares | $73,000,000 | $74,300,000 | $74,400,000 | $74,400,000 |
| Diluted NI Availto Com Stockholders | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Tax Provision | $107,500,000 | $122,300,000 | $114,700,000 | $107,200,000 |
| Gain On Sale Of Ppe | $0 | $-11,600,000 | $0 | $0 |
| Write Off | $7,300,000 | $9,600,000 | $6,200,000 | $5,600,000 |
| Restructuring And Mergern Acquisition | $2,600,000 | $-500,000 | $26,800,000 | $3,700,000 |
| Gain On Sale Of Security | $-10,200,000 | $-9,400,000 | $4,100,000 | $3,100,000 |
| Research And Development | $69,100,000 | $68,400,000 | $58,500,000 | $52,800,000 |
| Selling General And Administration | $338,500,000 | $353,400,000 | $316,900,000 | $362,800,000 |
| Impairment Of Capital Assets | - | $9,600,000 | $2,700,000 | $1,300,000 |
| Other Taxes | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $2,565,400,000 | $2,757,400,000 | $2,559,200,000 | $2,202,500,000 |
| Total Assets | $3,643,400,000 | $3,829,500,000 | $3,616,800,000 | $3,313,800,000 |
| Total Non Current Assets | $2,105,400,000 | $1,893,100,000 | $1,697,300,000 | $1,571,800,000 |
| Other Non Current Assets | $74,300,000 | $21,300,000 | $38,400,000 | $39,200,000 |
| Non Current Deferred Assets | $26,000,000 | $25,700,000 | $65,600,000 | $48,500,000 |
| Non Current Deferred Taxes Assets | $26,000,000 | $25,700,000 | $65,600,000 | $48,500,000 |
| Goodwill And Other Intangible Assets | $116,900,000 | $123,600,000 | $125,700,000 | $132,900,000 |
| Other Intangible Assets | $10,800,000 | $15,100,000 | $18,400,000 | $23,000,000 |
| Current Assets | $1,538,100,000 | $1,936,400,000 | $1,919,500,000 | $1,742,000,000 |
| Other Current Assets | $124,000,000 | $135,800,000 | $103,000,000 | $112,000,000 |
| Inventory | $377,000,000 | $434,700,000 | $414,800,000 | $378,400,000 |
| Receivables | $552,500,000 | $512,000,000 | $507,400,000 | $489,000,000 |
| Accounts Receivable | $552,500,000 | $512,000,000 | $507,400,000 | $489,000,000 |
| Allowance For Doubtful Accounts Receivable | $-800,000 | $-800,000 | $-200,000 | $-400,000 |
| Gross Accounts Receivable | $553,300,000 | $512,800,000 | $507,600,000 | $489,400,000 |
| Cash Cash Equivalents And Short Term Investments | $484,600,000 | $853,900,000 | $894,300,000 | $762,600,000 |
| Cash And Cash Equivalents | $484,600,000 | $853,900,000 | $894,300,000 | $762,600,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $302,300,000 | $309,000,000 | $317,900,000 | $325,300,000 |
| Long Term Debt And Capital Lease Obligation | $284,400,000 | $157,300,000 | $299,700,000 | $271,800,000 |
| Long Term Debt | $202,600,000 | $72,800,000 | $206,700,000 | $208,800,000 |
| Current Debt And Capital Lease Obligation | $17,900,000 | $151,700,000 | $18,200,000 | $53,500,000 |
| Current Debt | - | $134,000,000 | $2,200,000 | $44,200,000 |
| Other Current Borrowings | - | $134,000,000 | $2,200,000 | $44,200,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $961,100,000 | $948,500,000 | $931,900,000 | $978,400,000 |
| Total Non Current Liabilities Net Minority Interest | $410,700,000 | $276,700,000 | $412,900,000 | $384,300,000 |
| Other Non Current Liabilities | $62,200,000 | $58,500,000 | $51,600,000 | $38,200,000 |
| Non Current Deferred Liabilities | $35,900,000 | $31,300,000 | $33,400,000 | $33,800,000 |
| Non Current Deferred Taxes Liabilities | $20,500,000 | $12,700,000 | $14,300,000 | $4,900,000 |
| Current Liabilities | $550,400,000 | $671,800,000 | $519,000,000 | $594,100,000 |
| Other Current Liabilities | $57,400,000 | $39,500,000 | $32,100,000 | $29,300,000 |
| Current Deferred Liabilities | $49,600,000 | $41,700,000 | $57,300,000 | $48,700,000 |
| Payables And Accrued Expenses | $411,300,000 | $424,200,000 | $389,500,000 | $446,800,000 |
| Interest Payable | $1,600,000 | $2,600,000 | $2,500,000 | $3,200,000 |
| Payables | $304,800,000 | $288,200,000 | $272,700,000 | $284,900,000 |
| Dividends Payable | $15,200,000 | $14,800,000 | $14,100,000 | $13,400,000 |
| Total Tax Payable | $50,300,000 | $31,000,000 | $43,200,000 | $39,300,000 |
| Income Tax Payable | $31,400,000 | $16,600,000 | $24,800,000 | $26,300,000 |
| Accounts Payable | $239,300,000 | $242,400,000 | $215,400,000 | $232,200,000 |
| Minimum Pension Liabilities | - | - | $-9,400,000 | $-31,800,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $2,682,300,000 | $2,881,000,000 | $2,684,900,000 | $2,335,400,000 |
| Total Equity Gross Minority Interest | $2,682,300,000 | $2,881,000,000 | $2,684,900,000 | $2,335,400,000 |
| Stockholders Equity | $2,682,300,000 | $2,881,000,000 | $2,684,900,000 | $2,335,400,000 |
| Gains Losses Not Affecting Retained Earnings | $-258,100,000 | $-143,800,000 | $-183,000,000 | $-159,600,000 |
| Other Equity Adjustments | $-258,100,000 | $-143,800,000 | $-183,000,000 | $-159,600,000 |
| Retained Earnings | $3,956,600,000 | $3,523,400,000 | $2,987,800,000 | $2,456,700,000 |
| Long Term Equity Investment | $202,100,000 | $210,000,000 | $204,900,000 | $207,700,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $3,000,000 | $1,800,000 | $1,200,000 | $1,100,000 |
| Ordinary Shares Number | $72,300,000 | $73,500,000 | $74,100,000 | $74,200,000 |
| Share Issued | $75,300,000 | $75,300,000 | $75,300,000 | $75,300,000 |
| Tangible Book Value | $2,565,400,000 | $2,757,400,000 | $2,559,200,000 | $2,202,500,000 |
| Invested Capital | $2,884,900,000 | $3,087,800,000 | $2,893,800,000 | $2,588,400,000 |
| Working Capital | $987,700,000 | $1,264,600,000 | $1,400,500,000 | $1,147,900,000 |
| Capital Lease Obligations | $99,700,000 | $102,200,000 | $109,000,000 | $72,300,000 |
| Total Capitalization | $2,884,900,000 | $2,953,800,000 | $2,891,600,000 | $2,544,200,000 |
| Treasury Stock | $1,057,100,000 | $637,600,000 | $370,900,000 | $229,500,000 |
| Additional Paid In Capital | $22,100,000 | $120,200,000 | $232,200,000 | $249,000,000 |
| Capital Stock | $18,800,000 | $18,800,000 | $18,800,000 | $18,800,000 |
| Common Stock | $18,800,000 | $18,800,000 | $18,800,000 | $18,800,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $28,200,000 | $29,600,000 | $28,200,000 | $40,500,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $28,200,000 | $29,600,000 | $28,200,000 | $40,500,000 |
| Long Term Capital Lease Obligation | $81,800,000 | $84,500,000 | $93,000,000 | $63,000,000 |
| Current Deferred Revenue | $49,600,000 | $41,700,000 | $57,300,000 | $48,700,000 |
| Current Capital Lease Obligation | $17,900,000 | $17,700,000 | $16,000,000 | $9,300,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,600,000 | $10,900,000 | $10,600,000 | $11,200,000 |
| Current Provisions | $1,600,000 | $3,800,000 | $11,300,000 | $4,600,000 |
| Current Accrued Expenses | $106,500,000 | $136,000,000 | $116,800,000 | $161,900,000 |
| Investments And Advances | $202,100,000 | $210,000,000 | $204,900,000 | $207,700,000 |
| Goodwill | $106,100,000 | $108,500,000 | $107,300,000 | $109,900,000 |
| Net PPE | $1,686,100,000 | $1,512,500,000 | $1,262,700,000 | $1,126,800,000 |
| Accumulated Depreciation | $-1,404,200,000 | $-1,324,700,000 | $-1,228,300,000 | $-1,157,500,000 |
| Gross PPE | $3,090,300,000 | $2,837,200,000 | $2,491,000,000 | $2,284,300,000 |
| Construction In Progress | $410,800,000 | $415,200,000 | $305,900,000 | $242,700,000 |
| Other Properties | $274,000,000 | $263,700,000 | $258,900,000 | $208,800,000 |
| Machinery Furniture Equipment | $1,461,500,000 | $1,353,100,000 | $1,233,600,000 | $1,158,700,000 |
| Buildings And Improvements | $916,100,000 | $771,500,000 | $663,600,000 | $644,800,000 |
| Land And Improvements | $27,900,000 | $33,700,000 | $29,000,000 | $29,300,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $144,900,000 | $175,100,000 | $165,100,000 | $161,100,000 |
| Work In Process | $65,200,000 | $87,300,000 | $79,000,000 | $63,500,000 |
| Raw Materials | $166,900,000 | $172,300,000 | $170,700,000 | $153,800,000 |
| Foreign Currency Translation Adjustments | - | - | $-175,400,000 | $-128,100,000 |
| Defined Pension Benefit | - | - | $300,000 | $16,700,000 |
| Investmentsin Associatesat Cost | - | - | $204,900,000 | $207,700,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $276,400,000 | $414,500,000 | $439,400,000 | $330,600,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $653,400,000 | $776,500,000 | $724,000,000 | $584,000,000 |
| Cash Flow From Continuing Operating Activities | $653,400,000 | $776,500,000 | $724,000,000 | $584,000,000 |
| Operating Gains Losses | $-15,400,000 | $-5,200,000 | $20,100,000 | $-800,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-377,000,000 | $-362,000,000 | $-284,600,000 | $-253,400,000 |
| Investing Cash Flow | $-378,700,000 | $-368,700,000 | $-288,200,000 | $-253,100,000 |
| Cash Flow From Continuing Investing Activities | $-378,700,000 | $-368,700,000 | $-288,200,000 | $-253,100,000 |
| Net Other Investing Changes | $-1,700,000 | $-6,700,000 | $-3,600,000 | $2,500,000 |
| Capital Expenditure Reported | $-377,000,000 | $-362,000,000 | $-284,600,000 | $-253,400,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-566,600,000 | $-451,200,000 | $-222,200,000 | $-151,900,000 |
| Financing Cash Flow | $-622,600,000 | $-459,600,000 | $-293,600,000 | $-168,100,000 |
| Cash Flow From Continuing Financing Activities | $-622,600,000 | $-459,600,000 | $-293,600,000 | $-168,100,000 |
| Net Other Financing Charges | $-2,000,000 | $-100,000 | $-1,200,000 | - |
| Cash Dividends Paid | $-59,100,000 | $-57,000,000 | $-54,100,000 | $-51,100,000 |
| Net Common Stock Issuance | $-566,600,000 | $-451,200,000 | $-222,200,000 | $-151,900,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-192,300,000 | $-2,400,000 | $-44,300,000 | $-2,200,000 |
| Issuance Of Debt | $164,700,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $500,000 | $6,000,000 | $6,600,000 | $8,000,000 |
| Income Tax Paid Supplemental Data | $71,400,000 | $90,800,000 | $109,700,000 | $171,800,000 |
| End Cash Position | $484,600,000 | $853,900,000 | $894,300,000 | $762,600,000 |
| Beginning Cash Position | $853,900,000 | $894,300,000 | $762,600,000 | $615,500,000 |
| Effect Of Exchange Rate Changes | $-21,400,000 | $11,400,000 | $-10,500,000 | $-15,700,000 |
| Changes In Cash | $-347,900,000 | $-51,800,000 | $142,200,000 | $162,800,000 |
| Proceeds From Stock Option Exercised | $32,700,000 | $51,000,000 | $28,200,000 | $37,100,000 |
| Common Stock Payments | $-566,600,000 | $-451,200,000 | $-222,200,000 | $-151,900,000 |
| Net Issuance Payments Of Debt | $-27,600,000 | $-2,400,000 | $-44,300,000 | $-2,200,000 |
| Net Long Term Debt Issuance | $-27,600,000 | $-2,400,000 | $-44,300,000 | $-2,200,000 |
| Long Term Debt Payments | $-192,300,000 | $-2,400,000 | $-44,300,000 | $-2,200,000 |
| Long Term Debt Issuance | $164,700,000 | $0 | $0 | $0 |
| Change In Working Capital | $2,900,000 | $-20,400,000 | $-15,000,000 | $-198,100,000 |
| Change In Other Working Capital | $22,600,000 | $6,000,000 | $54,700,000 | $2,400,000 |
| Change In Other Current Assets | $-5,800,000 | $-21,300,000 | $18,500,000 | $-7,300,000 |
| Change In Payables And Accrued Expense | $2,900,000 | $4,400,000 | $-2,800,000 | $16,800,000 |
| Change In Payable | $2,900,000 | $4,400,000 | $-2,800,000 | $16,800,000 |
| Change In Account Payable | $2,900,000 | $4,400,000 | $-2,800,000 | $16,800,000 |
| Change In Inventory | $42,000,000 | $-13,500,000 | $-49,800,000 | $-86,500,000 |
| Change In Receivables | $-58,800,000 | $4,000,000 | $-35,600,000 | $-123,500,000 |
| Changes In Account Receivables | $-58,800,000 | $4,000,000 | $-35,600,000 | $-123,500,000 |
| Other Non Cash Items | $-4,700,000 | $1,000,000 | $13,300,000 | $-1,400,000 |
| Stock Based Compensation | $18,700,000 | $23,300,000 | $23,700,000 | $37,500,000 |
| Asset Impairment Charge | $7,300,000 | $9,600,000 | $6,200,000 | $5,600,000 |
| Deferred Tax | $-3,500,000 | $37,500,000 | $-30,800,000 | $-42,900,000 |
| Deferred Income Tax | $-3,500,000 | $37,500,000 | $-30,800,000 | $-42,900,000 |
| Depreciation Amortization Depletion | $155,400,000 | $137,300,000 | $120,600,000 | $122,300,000 |
| Depreciation And Amortization | $155,400,000 | $137,300,000 | $120,600,000 | $122,300,000 |
| Amortization Cash Flow | $3,600,000 | $3,600,000 | $3,700,000 | $5,400,000 |
| Amortization Of Intangibles | $3,600,000 | $3,600,000 | $3,700,000 | $5,400,000 |
| Depreciation | $151,800,000 | $133,700,000 | $116,900,000 | $116,900,000 |
| Pension And Employee Benefit Expense | $-2,000,000 | $-2,500,000 | $38,200,000 | $16,600,000 |
| Earnings Losses From Equity Investments | $-13,400,000 | $-14,300,000 | $-18,100,000 | $-17,400,000 |
| Gain Loss On Sale Of PPE | $0 | $11,600,000 | $0 | $0 |
| Net Income From Continuing Operations | $492,700,000 | $593,400,000 | $585,900,000 | $661,800,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-2,200,000 |
| Purchase Of Business | - | $0 | $0 | $-2,200,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |